Describing late Ajit Pawar as ’the best Chief Minister Maharashtra never had,’ Chief Minister Devendra Fadnavis paid an ...

It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions. Revenue in 2026 will be $59.5 ...

Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.

Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...